An interventional study of MyCog in Dementia, Cognitive Impairment and Cognitive Decline, sponsored by Northwestern University. Active, not recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Northwestern University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Alzheimer Disease by Northwestern University — 5 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Northwestern University.
Among the 16 studies in Alzheimer Disease by Northwestern University, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, and was the 10th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →5 of the 16 studies in Alzheimer Disease by Northwestern University are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 55+
Northwestern University · Sites in United States
Ages 60–90
Northwestern University · Sites in United States
Ages 55–100 · Healthy volunteers
Northwestern University · Sites in United States
Ages 18+ · Healthy volunteers
Northwestern University · Sites in United States
Ages 21+ · Healthy volunteers
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2024.
This study's enrollment of 57,589 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 105 across the 15 interventional studies, 0 across the 1 observational. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
4 of the studies in Alzheimer Disease by Northwestern University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07775625Northwestern UniversityCentral Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music | 2026-12-15 |
| NCT05477862Northwestern UniversityNeural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease | 2026-12-15 |
| NCT06112860Northwestern UniversityOTC Hearing Aid and MCI | 2026-12-31 |
| NCT05607732Northwestern UniversityPrimary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Alzheimer Disease by Northwestern University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and participating in the care planning and management of affected patients and caregivers. We will conduct a clinic-randomized, pragmatic trial testing the effectiveness and fidelity of our NIH Toolbox-derived paradigm to improve early detection and management of cognitive impairment/dementia in primary care settings serving health disparate patient populations.
Practical, scalable strategies are needed to help primary care practices better detect and manage cognitive impairment (CI), especially those caring for medically underserved, low socioeconomic status (SES) communities. Since 2017, our team has been a member of the Consortium for Detecting Cognitive Impairment, Including Dementia (DetectCID); a network dedicated to improving clinical paradigms for early detection of CI and Alzheimer's disease-related dementias (ADRD) and its subsequent management in everyday clinical settings. Having developed the NIH Toolbox for Assessment of Neurological and Behavioral Function and with expertise in health system re-design for patient-centered care, we validated our clinical paradigm, known as MyCog. This includes a brief, iPad-based, self-administered, electronic health record (EHR)-linked strategy to assess for CI during primary care visits when concerns are identified, and 'turnkey' recommendations to address them.
We will partner with a national primary care provider (Oak Street Health) and conduct a 2-arm, clinic-randomized, 'real world' pragmatic trial comparing MyCog to usual care. We will focus on populations experiencing CI/ADRD disparities: Black, H/L, and low SES older adults.
Our specific aims and hypotheses (H) are to:
Aim 1: Test the effectiveness of the MyCog paradigm to improve early detection of cognitive impairment and dementias among low SES, Black and Hispanic/Latino older adults.
Compared to usual care, primary care practices implementing MyCog will demonstrate:
H1: higher rates of detected and/or diagnosed cases of cognitive decline and impairment
Among detected and/or diagnosed cases of cognitive impairment, primary care practices implementing MyCog - compared to usual care - will have:
H2: a greater proportion of early stage (mild) cognitive impairments H3: more referrals for related medical and non-medical services H4: greater caregiver involvement in subsequent patient visits
Aim 2: Investigate the presence of disparities in early detection of cognitive impairment, its diagnosis, and rate of referrals by race and ethnicity.
H5: Disparities in early detection of CI, diagnosis, and referrals by race and ethnicity will be reduced among those primary care practices implementing MyCog compared to usual care.
Aim 3: Determine the fidelity and reliability of MyCog and identify any patient, caregiver, clinician, and/or health system barriers to its optimal, sustained implementation.
Aim 4: Assess the cost-effectiveness of the MyCog paradigm from a primary care perspective.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
This study's enrollment of 57,589 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The MyCog paradigm establishes a protocol for implementing our self-administered assessment in the clinic whenever a patient or involved family member reports a concern. The MyCog test can be completed either in the exam room or the waiting room. The MyCog app, on an iPad, can be readily linked to the electronic health record, so once the two tests are completed, results are securely transmitted and will populate within discrete, fields that can be queried found in the patient record; specifically: 1) in a screening tab, under 'cognitive abilities', 2) a flow sheet to capture trend with future repeated tests - informing physicians of a patient's relative vs. normative cognitive decline. Both a binary, objective classification of 'impairment detected or suspected' or 'no impairment detected' will populate in the record, as well as a summary score to further guide the clinician by clarifying the extent to which a patient's performance falls outside a normal threshold.
Diagnostic Test: MyCog
At Oak Street Health, cognitive assessments included when concerns are reported by patients or family members, if a clinician suspects a concern, or during Annual Wellness Visits (AWVs) are limited to the Mini-Cog©, and are variably administered, particularly outside of AWVs. Oak Street practices vary by clinician in terms of making referrals, how results are documented, what diagnosis code, placement in problem list or visit diagnosis, and any follow-up plans. While we will not make any explicit recommendations to usual care practices regarding their use of a cognitive assessment, we will ensure that 1) any chosen test is linked to a data field that can be queried in the EHR, and 2) providers receive a compiled list of local medical and non-medical referrals for any detected cases of CI. The Alzheimer's Association recommendations for early detection efforts among primary care practices will be provided to each clinical leadership.
MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
Rate of detected impairment
This will be operationalized as either results of an administered cognitive test suggesting impairment ('detected') or having any relevant International Classification of Diseases (ICD) 10 code recorded in a patient's record after the trial launch date and throughout follow-up observation period ('diagnosis').
Time frame: 3 years
Rate of detected cases with mild impairment
Mild vs. other impairment rates will be compared across trial arms, operationalized by ICD code groupings.
Time frame: 3 years
Rate of cognition-related referrals
Extraction from the electronic data warehouse for whether or not a cognitive-related referral was made (medical or non-medical) following a "detected" cognitive screen
Time frame: 3 years
Caregiver Involvement
Text search of clinic note from any follow-up visit post AWV, wellness visit mention of accompanying family member/caregiver; extraction from Enterprise Data Warehouse to determine if proxy access to patient's MyChart portal has been shared.
Time frame: 3 years
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 39 months is above that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Apr 2027, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.